Brief: Anavex: Oral Blarcamesine Shows Cognitive Resilience Near Normal Aging in Alzheimer’s Trial
09/09/2025 12:38
Sept 9 (Reuters) - Anavex Life Sciences Corp AVXL.O: ANAVEX LIFE SCIENCES ANNOUNCES ORAL BLARCAMESINE COGNITIVE RESILIENCE RESULTS APPROXIMATING NORMAL AGING IN NEW PRECISION MEDICINE CLINICAL DATA FROM PHASE IIB/III ALZHEIMER’S DISEASE TRIAL Source text: ID:nGNX77m2Hz Further company coverage: AVXL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Anavex Life Sciences
See all newsBrief: Anavex Provides Corporate Update, Announces Completion Of Clinical Conduct Of Adme And Ddi Clinical Studies
Brief: Anavex Receives FDA Clearance Of Its Ind Application For Blarcamesine In Fragile X Syndrome
Brief: Glass Lewis Recommends Anavex Stockholders To Vote For PVG’s Director Nominees
Brief: PVG Calls For Replacing Anavex Board, Hiring "Experienced" CEO
Brief: Pvg Asset Management- Nominates Six Director Candidates For Anavex Board